The significance of surgical staging in intermediate-risk endometrial cancer

Gynecologic Oncology

Volumn 122, Issue 1, 2011, Pages 50-54

  Kwon, Janice S ^a   Mazgani, Mona ^a   Miller, Dianne M ^a   Ehlen, Tom ^a   Heywood, Mark ^a   McAlpine, Jessica N ^a   Finlayson, Sarah J ^a   Plante, Marie ^a   Stuart, Gavin C E ^a   Carey, Mark S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Chemotherapy; Endometrial cancer; High risk; Intermediate risk; Nodal metastases; Surgical staging

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANADA; CANCER GRADING; CANCER INVASION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HYSTERECTOMY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; OVARIECTOMY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; LYMPH NODE EXCISION; MIDDLE AGED; NEOPLASM STAGING; OVARIECTOMY; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79957684299     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.02.037     Document Type: Article

References (36)

1. Canadian-Cancer-Society. Uterine cancer overview. In; 2010.
2. SEER. Age-Adjusted Total US Mortality Rates for Corpus and Uterus, NOS Cancer, All Ages, for 1969-2004. In; 2007.
3. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, Angioli R, Tateo S, Mangili G, Katsaros D, Garozzo G, Campagnutta E, Donadello N, Greggi S, Melpignano M, Raspagliesi F, Ragni N, Cormio G, Grassi R, Franchi M, Giannarelli D, Fossati R, Torri V, Amoroso M, Croce C, Mangioni C. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:1707-16.
4. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373:125-36.
5. Partridge EE, Shingleton HM, Menck HR. The National Cancer Data Base report on endometrial cancer. J Surg Oncol 1996;61:111-23. (Pubitemid 26066071)
6. Kwon JS, Qiu F, Saskin R, Carey MS. Are uterine risk factors more important than nodal status in predicting survival in endometrial cancer? Obstet Gynecol 2009;114:736-43.
7. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. Gynecol Oncol Group Study Cancer 1987;60:2035-41.
8. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24:36-44. (Pubitemid 46630491)
9. Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, van Bunningen BN, Ansink AC, van Putten WL, Creutzberg CL. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an openlabel, non-inferiority, randomised trial. Lancet 2010;375:816-23.
10. Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, Andersson H, Grenman S, Lundgren C, Rosenberg P, Boman K, Tholander B, Scambia G, Reed N, Cormio G, Tognon G, Clarke J, Sawicki T, Zola P, Kristensen G. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies. Eur J Cancer 2010.
11. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, Kudo R. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008;108:226-33. (Pubitemid 350299451)
12. Fanning J, Hoffman ML, Andrews SJ, Harrah AW, Feldmeier JJ. Cost effectiveness analysis treatment intermediate risk endometrial cancer postoperative brachytherapy vs. observation. Gynecol Oncol 2004;93:632-6. (Pubitemid 38766047)
13. Kwon JS, Carey MS, Goldie SJ, Kim JJ. Cost-effectiveness analysis of treatment strategies for Stage I and II endometrial cancer. J Obstet Gynaecol Can 2007;29:131-9.
14. Larson DM, Broste SK, Krawisz BR. Surgery without radiotherapy for primary treatment of endometrial cancer. Obstet Gynecol 1998;91:355-9. (Pubitemid 28119834)
15. Mohan DS, Samuels MA, Selim MA, Shalodi AD, Ellis RJ, Samuels JR, Yun HJ. Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma. Gynecol Oncol 1998;70:165-71. (Pubitemid 28430923)
16. Orr Jr JW, Holimon JL, Orr PF. Stage I corpus cancer: is teletherapy necessary? Am J Obstet Gynecol 1997;176:777-88 discussion 788-9.
17. Rittenberg PV, Lotocki RJ, Heywood MS, Jones KD, Krepart GV. High-risk surgical stage 1 endometrial cancer: outcomes with vault brachytherapy alone. Gynecol Oncol 2003;89:288-94. (Pubitemid 36457878)
18. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56:419-27. (Pubitemid 10018299)
19. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, DeWinter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E, Beerman H, van Lent M. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404-11.
20. Keysv HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA, Bell JG. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744-51. (Pubitemid 38251372)
21. Koper NP, Massuger LF, Thomas CM, Kiemeney LA, Verbeek AL. Serum CA 125 measurements to identify patients with endometrial cancer who require lymphadenectomy. Anticancer Res 1998;18:1897-902. (Pubitemid 28344846)
22. Chung HH, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand 2006;85:1501-5.
23. Dotters DJ. Preoperative CA 125 in endometrial cancer: is it useful? Am J Obstet Gynecol 2000;182:1328-34.
24. Hsieh CH, ChangChien CC, Lin H, Huang EY, Huang CC, Lan KC, Chang SY. Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol 2002;86:28-33.
25. Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol 1997;90:441-7. (Pubitemid 27357939)
26. Kitajima K, Suzuki K, Nakamoto Y, Onishi Y, Sakamoto S, Senda M, Kita M, Sugimura K. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence. Eur J Nucl Med Mol Imaging 37: 1490-8.
27. Nayot D, Kwon JS, Carey MS, Driedger A. Does preoperative positron emission tomography with computed tomography predict nodal status in endometrial cancer? A pilot study. Curr Oncol 2008;15:123-5.
28. Picchio M, Mangili G, Samanes Gajate AM, De Marzi P, Spinapolice EG, Mapelli P, Giovacchini G, Sigismondi C, Vigano R, Sironi S, Messa C. High-grade endometrial cancer: value of [(18)F]FDG PET/CT in preoperative staging. Nucl Med Commun 31: 506-12.
29. Signorelli M, Guerra L, Buda A, Picchio M, Mangili G, Dell'Anna T, Sironi S, Messa C. Role integrated FDG PET CT surgical management patients with high risk clinical early stage endometrial cancer detection pelvic nodal metastases. Gynecol Oncol 2009;115:231-5.
30. Abu-Rustum NR, Khoury-Collado F, Pandit-Taskar N, Soslow RA, Dao F, Sonoda Y, Levine DA, Brown CL, Chi DS, Barakat RR, Gemignani ML. Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? Gynecol Oncol 2009;113:163-9.
31. Barranger E, Delpech Y, Coutant C, Dubernard G, Uzan S, Darai E. Laparoscopic sentinel node mapping using combined detection for endometrial cancer: a study of 33 cases - is it a promising technique? Am J Surg 2009;197:1-7.
32. Delaloye JF, Pampallona S, Chardonnens E, Fiche M, Lehr HA, De Grandi P, Delaloye AB. Intraoperative lymphatic mapping and sentinel node biopsy using hysteroscopy in patients with endometrial cancer. Gynecol Oncol 2007;106:89-93. (Pubitemid 46898575)
33. Mais V, Peiretti M, Gargiulo T, Parodo G, Cirronis MG, Melis GB. Intraoperative sentinel lymph node detection by vital dye through laparoscopy or laparotomy in early endometrial cancer. J Surg Oncol 101: 408-12.
34. Perrone AM, Casadio P, Formelli G, Levorato M, Ghi T, Costa S, Meriggiola MC, Pelusi G. Cervical and hysteroscopic injection for identification of sentinel lymph node in endometrial cancer. Gynecol Oncol 2008;111:62-7.
35. Robova H, Charvat M, Strnad P, Hrehorcak M, Taborska K, Skapa P, Rob L. Lymphatic mapping in endometrial cancer: comparison of hysteroscopic and subserosal injection and the distribution of sentinel lymph nodes. Int J Gynecol Cancer 2009;19:391-4.
36. Bidus MA, Risinger JI, Chandramouli GV, Dainty LA, Litzi TJ, Berchuck A, Barrett JC, Maxwell GL. Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray. Clin Cancer Res 2006;12:83-8. (Pubitemid 43166180)